Shares of Exelixis EXEL increased in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 52.63% over the past year to $0.09, which beat the estimate of $0.03.
Revenue of $270,230,000 rose by 19.09% from the same period last year, which beat the estimate of $265,940,000.
Guidance
Exelixis Sees FY21 Revs $1.15B-$1.25B Vs $1.22B Est
Details Of The Call
Date: May 06, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/5x5fc2b8
Recent Stock Performance
Company's 52-week high was at $27.80
52-week low: $18.18
Price action over last quarter: Up 6.48%
Company Profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
